Page 340 - 2021_02-Haematologica-web

the therapeutic paradigm for marginal zone lymphoma is warranted.
Peter G. Miller,1 Adam S. Sperling,1 Christopher J. Gibson,1 Olga Pozdnyakova,2 Waihay J. Wong,2 Michael P. Manos,1 Elizabeth I. Buchbinder,1 F. Stephen Hodi,1 Benjamin L. Ebert,1,3 and Matthew S. Davids1
1Department of Medical Oncology, Dana-Farber Cancer Institute; 2Department of Pathology, Brigham and Women’s Hospital and 3Howard Hughes Medical Institute, Dana-Farber Cancer Institute, Boston, MA, USA
Correspondence: MATTHEW S. DAVIDS matthew_davids@DFCI.HARVARD.EDU
doi:10.3324/haematol.2020.258426
Disclosures: PGM has received consulting fees from Foundation Medicine, Inc. BLE has received research funding from Celgene, Deerfield, consulting fees from GRAIL, and is on the scientific advisory boards for Exo Therapeutics and Skyhawk Therapeutics. EIB.has received consulting fees from Novartis and Bristol Myers Squibb and clinical trial support from Merck and Bristol Myers Squibb. MSD has received research funding from Astra-Zeneca, Bristol Myers Squibb, Genentech, MEI Pharma, Pharmacyclics, Surface Oncology, TG Therapeutics and Verastem, and consulting fees from AbbVie, Adaptive Biotechnologies, Ascentage Pharma, Astra-Zeneca, BeiGene, Celgene, Genentech, Gilead Sciences, Janssen, MEI Pharma, Merck, Pharmacyclics, Syros Pharmaceuticals, TG Therapeutics, Verastem, and Zentalis. FSH has received research support from Novartis, con- sulting fees from Novartis, Genentech/Roche, Aduro, Sanofi, Kairos, and Pieris, sits on the advisory board for Takeda, Surface, Compass Therapeutic, Apricity, Pionyr, Verastem, Torque, Rheos, Bicara, and Amgen, and has equity in Apricity, Pionyr, Torque, and Kairos. Full ICMJE disclosure forms are available upon request.
Contributions: PGM, ASS, CJG, and MSD designed and con- ceived the study. MM, SH, EB, OP and WW collected the blood and bone marrow samples and processed the samples. PGM, ASS, CJG, and MSD.analyzed and interpreted the data. PGM, ASS and MSD drafted the manuscript. MSD and BLE obtained funding and super- vised the study.
Funding: PGM was supported by an Evans Foundation Young Investigator Award and American Society of Hematology Research Training Award for Fellows. ASS was supported by Ruth L. Kirschstein National Research Service Award and a Conquer Cancer Foundation Young Investigator Award. This work was supported by the NIH (R01HL082945 and P01CA108631), the Howard Hughes Medical Institute, the Edward P. Evans Foundation, and the Leukemia & Lymphoma Society to BLE. MSD is a Scholar in Clinical Research from the Leukemia & Lymphoma Society.
References
1. Kluk MJ, Lindsley RC, Aster JC, et al. Validation and implementation of a custom next-generation sequencing clinical assay for hmatologic malignancies. J Mol Diagn. 2016;18(4):507-515.
2. Matutes E, Oscier D, Montalban C, et al. Splenic marginal zone lym- phoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia. 2008;22(3):487-495.
3. Mollejo M, Lloret E, Menarguez J, Piris MA, Isaacson PG. Lymph node involvement by splenic marginal zone lymphoma: morpholog- ical and immunohistochemical features. Am J Surg Pathol. 1997; 21(7):772-780.
4. Kennedy SR, Schmitt MW, Fox EJ, et al. Detecting ultralow-frequen- cy mutations by Duplex Sequencing. Nat Protoc. 2014;9(11):2586- 2606.
5. Bondar G, Cadeiras M, Wisniewski N, et al. Comparison of whole blood and peripheral blood mononuclear cell gene expression for evaluation of the perioperative inflammatory response in patients with advanced heart failure. PLoS One. 2014;9(12):e115097.
6. Garcia EP, Minkovsky A, Jia Y, et al. Validation of OncoPanel: a tar- geted next-generation sequencing assay for the detection of somatic variants in cancer. Arch Pathol Lab Med. 2017;141(6):751-758.
7. Lui YY, Chik KW, Chiu RW, Ho CY, Lam CW, Lo YM. Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex- mismatched bone marrow transplantation. Clin Chem. 2002; 48(3):421-427.
8. Ptashkin RN, Mandelker DL, Coombs CC, et al. Prevalence of clonal hematopoiesis mutations in tumor-only clinical genomic profiling of solid tumors. JAMA Oncol. 2018;4(11):1589-1593.
9. Razavi P, Li BT, Brown DN, et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat Med. 2019;25(12):1928-1937.
10. Hu Y, Ulrich BC, Supplee J, et al. False-positive plasma genotyping due to clonal hematopoiesis. Clin Cancer Res. 2018;24(18):4437- 4443.
11. Mohamedali AM, Gaken J, Ahmed M, et al. High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS). Leukemia. 2015;29(9):1928-1938.
12. Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34(23):2698-2704.
13. Ding W, LaPlant BR, Call TG, et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood. 2017;129(26):3419-3427.
14. Panjwani PK, Charu V, DeLisser M, Molina-Kirsch H, Natkunam Y, Zhao S. Programmed death-1 ligands PD-L1 and PD-L2 show dis- tinctive and restricted patterns of expression in lymphoma subtypes. Hum Pathol. 2018;71:91-99.
15. Vranic S, Ghosh N, Kimbrough J, et al. PD-L1 status in refractory lymphomas. PLoS One. 2016;11(11):e0166266.
16. Vincent-Fabert C, Soubeyran I, Velasco V, et al. Inflamed phenotype of splenic marginal zone B-cell lymphomas with expression of PD- L1 by intratumoral monocytes/macrophages and dendritic cells. Cell Mol Immunol. 2019;16(6):621-624.
17. Kastenhuber ER, Lowe SW. Putting p53 in context. Cell. 2017;170(6):1062-1078.
18. Boettcher S, Miller PG, Sharma R, et al. A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignan- cies. Science. 2019;365(6453):599-604.
19.Jaramillo Oquendo C, Parker H, Oscier D, Ennis S, Gibson J, Strefford JC. Systematic review of somatic mutations in splenic mar- ginal zone lymphoma. Sci Rep. 2019;9(1):10444.
20. Parry M, Rose-Zerilli MJ, Ljungstrom V, et al. Genetics and prognos- tication in splenic marginal zone lymphoma: revelations from deep sequencing. Clin Cancer Res. 2015;21(18):4174-4183.
654
haematologica | 2021; 106(2)
Case Reports